Medical University Of Graz

At Medical University of Graz the Gynaecology Department collaborates on cardiovascular research focusing on heart failure, acute myocardial infarction and stroke prevention.

• Heart failure with reduced ejection fraction
• Acute myocardial infarction (AMI)
• Prevention of ischemic stroke after TIA
• Left ventricular thrombus management
• Atrial fibrillation and anticoagulation

These studies aim to evaluate new therapies and improve outcomes for patients with serious heart and vascular conditions.

The Gynaecology Department supports investigations into liver and metabolic disorders such as non‑alcoholic steatohepatitis and Alpha‑1 antitrypsin deficiency.

• Non‑alcoholic steatohepatitis (NASH)
• Alpha‑1 antitrypsin deficiency‑associated liver disease
• Obesity‑related liver injury
• Metabolic syndrome interventions
• Liver fibrosis reduction

The goal is to test novel agents that can halt disease progression and improve liver health.

Ophthalmology trials at the university evaluate treatments for macular edema and uveitic complications to preserve vision.

• Macular edema secondary to retinal vein occlusion
• Uveitic macular edema
• Best‑corrected visual acuity outcomes
• Intravitreal drug delivery
• Safety of retinal injections

These investigations seek to reduce retinal swelling using innovative biologics.

Studies on blood‑related cancers and disorders include lymphoma, leukemia, and rare hematologic conditions.

• Large B‑cell lymphoma (LBCL)
• Follicular lymphoma
• Acute myeloid leukemia
• Ewing sarcoma (hematologic aspects)
• Graft‑versus‑host disease monitoring

Efforts focus on assessing efficacy of targeted therapies and improving survival in patients with aggressive blood cancers.

Endocrine research explores growth hormone deficiency, reproductive cancers, and metabolic hormone disorders.

• Growth hormone deficiency in adolescents
• ER+/HER2‑ negative breast cancer
• Advanced ovarian cancer
• Hormone‑driven endometrial cancer
• Metabolic hormone modulation

Trials aim to refine hormonal treatments and evaluate new agents that influence disease recurrence and quality of life.

Immune‑mediated conditions such as Sjögren’s syndrome, atopic dermatitis and Goodpasture disease are under investigation.

• Sjogren’s syndrome
• Atopic dermatitis (AD)
• Prurigo nodularis
• Anti‑GBM antibody disease
• Hidradenitis suppurativa

The purpose is to test immunomodulatory drugs that can reduce inflammation and improve skin and organ health.

A broad oncology program addresses solid tumors and hematologic malignancies, from melanoma to lung cancer.

• Melanoma (resected stage IIB/C)
• Metastatic non‑small cell lung cancer
• Advanced breast cancer
• Endometrial carcinoma
• Ewing sarcoma

These trials evaluate new chemotherapies, immunotherapies and targeted agents to increase survival and disease‑free intervals.

Metabolic research focuses on diabetes, obesity and related cardiovascular risk.

• Type 2 diabetes
• Obesity and overweight
• Cardiovascular risk in diabetic patients
• Metabolic syndrome
• Weight‑loss interventions

The aim is to compare novel glucose‑lowering agents and weight‑management strategies for better metabolic control.

Dermatology trials investigate chronic skin conditions and their systemic impact.

• Atopic dermatitis
• Prurigo nodularis
• Hidradenitis suppurativa
• Skin fibrosis in systemic diseases
• Connective tissue disorder monitoring

Research seeks effective topical and systemic therapies to alleviate symptoms and prevent disease progression.

Additional studies cover areas that do not fit into a single therapeutic category, including rare disorders and innovative diagnostic approaches.

• Rare genetic liver disease
• Novel anticoagulation reversal agents
• Advanced imaging biomarkers
• Patient‑reported outcome tools
• Safety of emerging biologics

These projects broaden the scientific portfolio of Medical University of Graz and support interdisciplinary collaboration.